4 results
CAEB071A2206 will assess safety, efficacy and target trough levels for optimal dosing of AEB071 combined with Certican in a CNI-free regimen in de novo renal transplant recipients. This study will combine the investigational drug AEB071 with an…
The primary hypotheses in this study is that a cangrelor infusion will maintain target levels of platelet inhibition (> 60% inhibition) after discontinuation of a thienopyridine (clopidogrel or ticlopidine) in patients waiting for surgery.
The main objective of this treatment protocol is to study the efficacy on the treatment response after adding a single gift of Mylotarg. Furthermore, monitoring of toxicity and long term efficacy is also important.
To evaluate the safety, tolerability, PK, PD and efficacy of intravenous (IV) ATB200 alone and when co-administered with oral AT2221.